PriceTargets.com logo

Genetron - GTH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 852.38%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.05 As of 03/31/2023 01:00 AM ET
▼ -0.01 (-0.94%)

This chart shows the closing price for GTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genetron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTH

Analyst Price Target is $10.00
▲ +852.38% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genetron in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 852.38% upside from the last price of $1.05.

This chart shows the closing price for GTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Genetron.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/21/2022BTIG ResearchLower TargetBuy$17.00 ➝ $10.00High
9/24/2021BTIG ResearchReiterated RatingBuy$25.00 ➝ $21.00Low
7/14/2020BTIG ResearchInitiated CoverageBuy$20.00High
(Data available from 4/1/2018 forward)

News Sentiment Rating

-0.59 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Genetron logo
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Read More

Today's Range

Now: $1.05
Low: $1.03
High: $1.09

50 Day Range

MA: $1.05
Low: $0.91
High: $1.23

52 Week Range

Now: $1.05
Low: $0.73
High: $3.01

Volume

8,850 shs

Average Volume

25,226 shs

Market Capitalization

$96.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Genetron?

The following sell-side analysts have issued research reports on Genetron in the last twelve months: BTIG Research.
View the latest analyst ratings for GTH.

What is the current price target for Genetron?

1 Wall Street analysts have set twelve-month price targets for Genetron in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 852.4%. BTIG Research has the highest price target set, predicting GTH will reach $10.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $10.00 for Genetron in the next year.
View the latest price targets for GTH.

What is the current consensus analyst rating for Genetron?

Genetron currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GTH will outperform the market and that investors should add to their positions of Genetron.
View the latest ratings for GTH.

What other companies compete with Genetron?

Other companies that are similar to Genetron include DermTech, Personalis, Sera Prognostics, Akumin and Enzo Biochem. Learn More about companies similar to Genetron.

How do I contact Genetron's investor relations team?

Genetron's physical mailing address is 1-2/F BUILDING 11 ZONE 1 CHANGPING DISTRICT, BEIJING F4, 102206. The company's listed phone number is 86-10-5090-7500 and its investor relations email address is [email protected] The official website for Genetron is www.genetronhealth.com. Learn More about contacing Genetron investor relations.